Setara Biosciences launched with $90 million in Series A funding and a genetics-led pipeline built on programs carried forward from Actio Biosciences after Jazz Pharmaceuticals acquired Actio’s ABS-1230 epilepsy asset. Setara’s lead candidate, STAR-0871, is a small-molecule TRPV4 inhibitor derived from Actio’s ABS-0871 program. The company is targeting Charcot-Marie-Tooth disease type 2C (gain-of-function mutations in TRPV4), a rare inherited neuromuscular disorder affecting an estimated 2,500 people in the US. Setara’s approach aims to block an overactive ion channel at the genetic root rather than provide symptom management. Setara’s funding round reportedly includes continuity from Actio’s investor base, with Jazz joining as a new shareholder following its acquisition. The company also plans to translate the same biology into broader indications, including extending TRPV4 biology into overactive bladder, describing a “one to many” translational strategy. The launch is notable for how acquisition carve-outs are being used to preserve platform momentum—especially in rare disease genetics—while retooling assets for next-stage clinical development under new ownership.